Antiplatelet therapy for secondary prevention in patients with ischaemic stroke and transient ischaemic attack: a retrospective cohort study in Malaysia

In this study, we evaluated clinical outcomes of antiplatelet therapy for secondary prevention in ischaemic stroke and transient ischaemic attack (TIA) patients. This was a retrospective cohort study that included patients with newly diagnosed ischaemic stroke or TIA between 2014 and 2017 using d...

Full description

Bibliographic Details
Main Authors: Ab Rahman N, Law Wc, Pang SHL, Wong WY, Sivasampu S
Format: Article
Language:English
Published: Penerbit UKM 2023
Online Access:http://journalarticle.ukm.my/24400/
http://journalarticle.ukm.my/24400/1/MH_12pdf_.pdf
_version_ 1848816093819305984
author Ab Rahman N,
Law Wc,
Pang SHL,
Wong WY,
Sivasampu S,
author_facet Ab Rahman N,
Law Wc,
Pang SHL,
Wong WY,
Sivasampu S,
author_sort Ab Rahman N,
building UKM Institutional Repository
collection Online Access
description In this study, we evaluated clinical outcomes of antiplatelet therapy for secondary prevention in ischaemic stroke and transient ischaemic attack (TIA) patients. This was a retrospective cohort study that included patients with newly diagnosed ischaemic stroke or TIA between 2014 and 2017 using data from routine practice in Malaysia. Patients were grouped into single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) users. Primary outcome was composite of stroke, myocardial infarction, and all-cause death in 90 days and 1 year. Safety outcome was major bleeding events. Among 3344 stroke patients, 8.1% received DAPT and 91.2% received SAPT. The 1-year cumulative incidence of composite events was 16.0 and 7.2 per 100 person-years for SAPT and DAPT, respectively. Propensity score-matched analysis of Cox hazard model showed DAPT reduced the risk of composite event (hazard ratio (HR) 0.48; 95% CI 0.25-0.91) and recurrent stroke (HR 0.38; 95% CI 0.16-0.92) in 1-year follow-up. Results were not significant for myocardial infarction, all-cause death, and 90-day outcomes. The risks of bleeding were not significantly different between SAPT and DAPT. Treatment with DAPT after an ischaemic stroke/TIA was associated with reduced risk of the composite events (stroke, myocardial infarction, or death) and recurrent stroke at 1 year.
first_indexed 2025-11-15T01:00:24Z
format Article
id oai:generic.eprints.org:24400
institution Universiti Kebangasaan Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T01:00:24Z
publishDate 2023
publisher Penerbit UKM
recordtype eprints
repository_type Digital Repository
spelling oai:generic.eprints.org:244002024-10-18T07:44:51Z http://journalarticle.ukm.my/24400/ Antiplatelet therapy for secondary prevention in patients with ischaemic stroke and transient ischaemic attack: a retrospective cohort study in Malaysia Ab Rahman N, Law Wc, Pang SHL, Wong WY, Sivasampu S, In this study, we evaluated clinical outcomes of antiplatelet therapy for secondary prevention in ischaemic stroke and transient ischaemic attack (TIA) patients. This was a retrospective cohort study that included patients with newly diagnosed ischaemic stroke or TIA between 2014 and 2017 using data from routine practice in Malaysia. Patients were grouped into single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) users. Primary outcome was composite of stroke, myocardial infarction, and all-cause death in 90 days and 1 year. Safety outcome was major bleeding events. Among 3344 stroke patients, 8.1% received DAPT and 91.2% received SAPT. The 1-year cumulative incidence of composite events was 16.0 and 7.2 per 100 person-years for SAPT and DAPT, respectively. Propensity score-matched analysis of Cox hazard model showed DAPT reduced the risk of composite event (hazard ratio (HR) 0.48; 95% CI 0.25-0.91) and recurrent stroke (HR 0.38; 95% CI 0.16-0.92) in 1-year follow-up. Results were not significant for myocardial infarction, all-cause death, and 90-day outcomes. The risks of bleeding were not significantly different between SAPT and DAPT. Treatment with DAPT after an ischaemic stroke/TIA was associated with reduced risk of the composite events (stroke, myocardial infarction, or death) and recurrent stroke at 1 year. Penerbit UKM 2023 Article PeerReviewed application/pdf en http://journalarticle.ukm.my/24400/1/MH_12pdf_.pdf Ab Rahman N, and Law Wc, and Pang SHL, and Wong WY, and Sivasampu S, (2023) Antiplatelet therapy for secondary prevention in patients with ischaemic stroke and transient ischaemic attack: a retrospective cohort study in Malaysia. Medicine & Health, 18 (2). pp. 480-497. ISSN 1823-2140 https://medicineandhealthukm.com/toc/18/2
spellingShingle Ab Rahman N,
Law Wc,
Pang SHL,
Wong WY,
Sivasampu S,
Antiplatelet therapy for secondary prevention in patients with ischaemic stroke and transient ischaemic attack: a retrospective cohort study in Malaysia
title Antiplatelet therapy for secondary prevention in patients with ischaemic stroke and transient ischaemic attack: a retrospective cohort study in Malaysia
title_full Antiplatelet therapy for secondary prevention in patients with ischaemic stroke and transient ischaemic attack: a retrospective cohort study in Malaysia
title_fullStr Antiplatelet therapy for secondary prevention in patients with ischaemic stroke and transient ischaemic attack: a retrospective cohort study in Malaysia
title_full_unstemmed Antiplatelet therapy for secondary prevention in patients with ischaemic stroke and transient ischaemic attack: a retrospective cohort study in Malaysia
title_short Antiplatelet therapy for secondary prevention in patients with ischaemic stroke and transient ischaemic attack: a retrospective cohort study in Malaysia
title_sort antiplatelet therapy for secondary prevention in patients with ischaemic stroke and transient ischaemic attack: a retrospective cohort study in malaysia
url http://journalarticle.ukm.my/24400/
http://journalarticle.ukm.my/24400/
http://journalarticle.ukm.my/24400/1/MH_12pdf_.pdf